Alexander Zapesochny

Alex Zapesochny co-founded iCardiac Technologies in 2006, which successfully commercialized technologies from the University of Rochester and from Pfizer for better determining whether new pharmaceutical products are safe for the heart. The company went on to serve the majority of the largest global pharma companies and its research led to significant regulatory changes for streamlining cardiac safety testing in drug development. iCardiac was acquired by the private equity firm Norwest Venture Partners in 2014 and then, under Alex serving as CEO, was acquired in late 2017 by ERT (owned by Nordic Capital). Previously, he was part of the executive management team of Lenel Systems, a fast-growing developer of enterprise software, hardware and services for the electronic security industry that was acquired by United Technologies. Alex currently serves as Chairman of the Board to Clerio Vision, a vision correction company based on University of Rochester research. His other roles have included being a trial attorney during his tenure as a New York City prosecutor, a policy division staff member in the Washington headquarters of a presidential campaign, and co-founder of an award-winning healthcare non-profit. Alex participates in various community activities, including as a member of the Entrepreneurship & Development Working Group of the Finger Lakes Regional Economic Development Council, as a Trustee of the Center for Governmental Research and as a Board member for a Rochester-based charter school. Alex received his undergraduate degree from Cornell University and graduate degrees from American University and the University of Oxford.